



## FOUNDERS

**James Prudent**  
**Jon Thorson**  
**C. Richard Hutchinson**

## MANAGEMENT TEAM

**James Prudent**  
*CEO and Chairman*  
**Steve Worsley**  
*Chief Business Officer*  
**David Marshall**  
*Director of Biology*  
**Mohammed S. Shekhani**  
*Director of Chemistry*

## BOARD

**Dr. James Prudent**  
**Dr. Troy Wilson**  
**Dr. Ray Schinazi**  
**Dr. Jon Thorson**  
**Mr. Hayden Leason**

## ADVISORS - expertise

**Kevin Kaster**—Intellectual Property  
**Homer Pearce** - Oncology  
**Paul Anderson**—Drug Development  
**Gary Ward** – ADC Manufacturing  
**Stan Roberts** – ADC Toxicology  
**Phil Hammon** – ADC Development

## CONTACT US

**James Prudent**  
**CEO**  
**Centrose LLC**  
**802 Deming Way**  
**Madison, WI, 53717**  
**Tel: (608) 209-8933**  
**E-mail:**  
[prudent@centrosepharma.com](mailto:prudent@centrosepharma.com)

## SUMMARY

Centrose discovered the first-ever synergistic drug targeting system called the Extracellular Drug Conjugate System or EDC. EDCs are like Antibody Drug Conjugates (ADCs) but are safer and more effective because they are not pro-drugs and only effect diseased cells. EDCs are simply the most selective drugs ever discovered. To modulate cell growth and activity, EDCs use Mabs (specific to diseased cells) and attached modulating drugs that work in concert together – the two must be attached to work. Currently, Centrose has 4 EDC lead drug candidates and is continuing to build the pipeline and platform. As a platform, the EDC system allows for the construction of targeted drugs that can be developed for multiple indications including cancer, inflammation and diabetes.

## BUSINESS

Our Business is focused on producing the next generation of targeted therapies and to out-license our assets to select pharmaceutical companies. Our business plan is centered on producing patented EDC drug candidates in large markets where the need for new drugs persists, then to license those products to select companies. To save money, time and to focus our resources, Centrose outsources manufacturing to a well-established CMO and concentrate resources on discovering new drug leads, advancing the EDC system and securing assets. Strategic partnering is therefore a critical component of our ability to advance Centrose's novel therapeutics programs into clinical development and onto the market.

## PRODUCTS

Centrose currently has 4 EDCs ready for licensing. EDC1 was the first EDC and has shown efficacy against one of the most aggressive tumor types known: non-small-cell lung cancer (NSCLC). EDC2 has shown strong efficacy toward multiple cancer types. EDC3 and EDC4 are selective toward specific diseased cell types. All require two complexed targets located on the surface of diseased cells in order to work.

## INTELLECTUAL PROPERTY

Centrose technology is currently the sole property of Centrose. Centrose has applied for multiple US and World-Wide patents covering EDC technology. Centrose also has the freedom-to-operate in the space.

## ACCOMPLISHED TEAM

**James Prudent, CEO.** Dr. Prudent brings over 25 years of scientific business expertise to Centrose. Prior to Centrose he worked at EraGen, Third Wave and IGEN International. He obtained his PhD from UC-Berkeley in the Department of Chemistry under the direction of Peter G. Schultz.

**Steve Worsley, CBO.** Mr. Worsley brings over 25 years in the biotechnology industry to Centrose. Mr. Worsley has executed numerous business transactions in the antibody drug market; most notably with the companies Abgenix, Inc. and Raven Biotechnology where he was responsible for out-licensing each of the company's clinical-level assets.

**David Marshal, Director of Biology.** Mr. Marshall brings over 20 years of broad biotechnology experience to Centrose. Prior to Centrose, he worked at EraGen Biosciences (now Luminex) and Third Wave Technologies (now Hologics). His areas of expertise include; cancer genetics, nucleic acid chemistry, molecular biology, biochemistry, cell culture, animal science and chemoprevention.

**Mohammed Shekhani, Director of Chemistry.** Dr. Shekhani brings over 25 years of experience to Centrose. Prior to joining Centrose, he worked at PanVera (now Invitrogen) and Sandoz (now Novartis). His expertise is medicinal organic chemistry. He received his PhD in Synthetic Organic Chemistry from State University of New York at Stony Brook.